1
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 27, 2022Recruiting
Jackson-Weiss Syndrome: 21 Clinical Trials, Page 1 of 3
Hide Studies Not Open or Pending
2
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene RearrangementsLast Updated:May 18, 2022Recruiting
3
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:November 9, 2021Active, not recruiting
4
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Condition(s):Advanced CholangiocarcinomaLast Updated:May 12, 2022Available
5
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Condition(s):Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and CholangiocarcinomaLast Updated:June 14, 2022Active, not recruiting
6
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Condition(s):Solid TumorsLast Updated:April 13, 2022Not yet recruiting
7
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Condition(s):CholangiocarcinomaLast Updated:March 10, 2022Recruiting
8
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Condition(s):Gastric Cancer; Gastroesophageal Junction AdenocarcinomaLast Updated:June 16, 2022Recruiting
9
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Condition(s):Medical OncologyLast Updated:July 12, 2017Terminated
10
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Condition(s):Gastric Cancer; Gastroesophageal Junction CancerLast Updated:June 16, 2022Recruiting